Karlberg B E, Kågedal B, Tegler L, Tolagen K, Bergman B
Am J Cardiol. 1976 Mar 31;37(4):642-9. doi: 10.1016/0002-9149(76)90409-4.
Twenty-seven patients with hypertension were randomly allocated to a 10 month crossover study. Treatment consisted of spironolactone (200 mg/day for 2 months), propranolol (320 mg/day for 2 months) and combined administration of both drugs at half the dosage. Between treatment periods placebo was given for 2 months. Fourteen patients were previously untreated. The average pretreatment blood pressure for the entire group was 188/114 +/- 16/7(mean +/- standard deviation) mm Hg supine and 188/118 +/- 20/9 mm Hg standing. Both spironolactone and propranolol reduced blood pressure significantly in both the supine and standing positions. Upright plasma renin activity was determined by radioimmunoassay of angiotensin I. The average initial level was 1.9 +/- 1.2 (range 0.4 to 5.0) ng/ml/hr. There was a close correlation between plasma renin activity and the effects of the drugs: With increasing renin level the response to propranolol was better whereas the opposite was true for spironolactone. The combination of spironolactone and propranolol decreased the blood pressure still further in the supine and standing positions, irrespective of initial plasma renin activity. All patients achieved a normal supine pressure. Blood pressure and plasma renin activity returned toward pretreatment values during placebo administration. It is concluded that pretreatment levels of plasma renin activity can predict the antihypertensive response to propranolol and spironolactone. The combination of the two drugs, which have different modes of action, will effectively reduce blood pressure in hypertension. The results support the concept that the renin-angiotensin-aldo-sterone system may be involved in primary hypertension.
27例高血压患者被随机分配到一项为期10个月的交叉研究中。治疗包括螺内酯(200毫克/天,持续2个月)、普萘洛尔(320毫克/天,持续2个月)以及两种药物以一半剂量联合使用。在治疗周期之间给予2个月的安慰剂。14例患者此前未接受过治疗。整个组的平均治疗前血压仰卧位为188/114±16/7(均值±标准差)毫米汞柱,站立位为188/118±20/9毫米汞柱。螺内酯和普萘洛尔在仰卧位和站立位均显著降低血压。通过对血管紧张素I进行放射免疫测定来确定直立位血浆肾素活性。平均初始水平为1.9±1.2(范围0.4至5.0)纳克/毫升/小时。血浆肾素活性与药物效果之间存在密切相关性:随着肾素水平升高,对普萘洛尔的反应更好,而对螺内酯则相反。无论初始血浆肾素活性如何,螺内酯和普萘洛尔联合使用在仰卧位和站立位进一步降低了血压。所有患者仰卧位血压均恢复正常。在给予安慰剂期间,血压和血浆肾素活性恢复到治疗前水平。结论是,血浆肾素活性的治疗前水平可以预测对普萘洛尔和螺内酯的降压反应。两种作用方式不同的药物联合使用将有效降低高血压患者的血压。结果支持肾素 - 血管紧张素 - 醛固酮系统可能参与原发性高血压的概念。